Comparative Effects of Perindopril with Enalapril in Rats with Dilated Cardiomyopathy

Journal of Cardiovascular Pharmacology

Volumn 42, Issue SUPPL. 1, 2003, Pages

  Watanabe, Kenichi ^a   Saito, Yuki ^a   Ma, Meilei ^a   Wahed, Mir ^a   Abe, Yuichi ^a   Hirabayashi, Kenichi ^a   Narasimman, Gurusamy ^a   Wen, Juan ^a   Suresh, Palaniyandi ^a   Ali, Fadia ^a   Shirai, Ken ^a   Soga, Mayako ^a   Nagai, Yusuke ^a   Nakazawa, Mikio ^b   Hasegawa, Go ^b   Naito, Makoto ^b   Tachikawa, Hitoshi ^b   Kodama, Makoto ^b   Aizawa, Yoshifusa ^b   Yamaguchi, Kenichi ^b   Takahashi, Toshihiro ^b   more..

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

Angiotensin; Angiotensin converting enzyme inhibitor; Enalapril; Heart failure; Perindopril; Transforming growth factor

Indexed keywords

COLLAGEN TYPE 3; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; MESSENGER RNA; PERINDOPRIL; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HEART DILATATION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE FUNCTION; IMMUNIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 10744220736     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200312001-00022     Document Type: Conference Paper

References (21)

1. CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
2. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of congestive heart failure. N Engl J Med 1991;324:303-10.
3. SOLVD investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
4. Weinberg EO, Schoen FJ, George D, et al. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 1994;90:1410-22.
5. Litwin SE, Kats SE, Weinberg EO, et al. Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. Circulation 1995;91:2642-54.
6. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-69.
7. Linz W, Wiemer G, Gohlke P, et al. Contributions of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995;47:25-49.
8. Musuelli M, Brusca G, Pardo A, et al. ACE inhibitors in heart failure-switching from enalapril to perindopril. Curr Med Res Opin 2002;18:296-302.
9. Mizuno Y, Yasue H, Yoshimura M, et al. Effects of perindopril on aldosterone in the failing human heart. Am J Cardiol 2002;89:1197-200.
10. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-65.
11. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 199;79:215-62.
12. Powell J, Clozel J, Muller R, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-8.
13. Schelling P, Fisher PH, Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy. J Hypertens 1991;9:3-15.
14. Ma M, Watanabe K, Wahed II M, et al. Inhibition of progression of heart failure and expression of TGF-β1 mRNA in rats with heart failure by the ACE inhibitor quinapril. J Cardiovasc Pharmacol 2001;38:S51-S54.
15. Kodama M, Hanawa H, Saeki M, et al. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res 1994;75:278-84.
16. Watanabe K, Ohta Y, Nakazawa M, et al. Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. Br J Pharmacol 2000;130:1489-95.
17. Ruzicka M, Skarda V, Leenen HHF, et al. Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats. Circulation 1995;92:3568-73.
18. Ohta Y, Watanabe K, Nakazawa M, et al. Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart. J Cardiovasc Pharmacol 2000;36 (suppl. 2):S19-S23.
19. Chomczynski P, Sacchi N. Single-step method of mRNA by acid guaniginium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
20. Fujinaka H, Yamamoto T, Feng L, et al. Crucial role of CD8-positive lymphocytes in glomerular expression of ICAM-1 and cytokines in crescentic glomerulonephritis of WKY rats. J Immunol 1997;158:4978-83.
21. Juan W, Nakazawa M, Watanabe K, et al. Quinapril inhibits progression of heart failure and fibrosis in rats with dilated cardiomyopathy after myocarditis. Mol Cell Biochem 2003 (in press).